Download PDF
Thromb Haemost 1976; 36(02): 451-464
DOI: 10.1055/s-0038-1648060
Original Article
Schattauer GmbH

Enhancement of Fibrinolytic and Thrombolytic Potential in the Rat by Treatment with an Anabolic Steroid, Furazabol

Toshihiko Kumada
1   Research Institute, Daiichi Seiyaku Co., Ltd., Edogawa-ku, Tokyo 132, Japan
,
Yasushi Abiko
1   Research Institute, Daiichi Seiyaku Co., Ltd., Edogawa-ku, Tokyo 132, Japan
› Author Affiliations
Further Information

Publication History

Received 20 February 1975

Accepted 21 May 1976

Publication Date:
03 July 2018 (online)

    Permissions and Reprints

Summary

The effect of long-term ingestion of an anabolic steroid, furazaboi, was studied on coagulo-fibrinolytic systems in the rat.

During the administration of furazabol at the daily dose of 0.04, 0.2 or 1 mg/rat for 3 months, the most remarkable changes were increase in the plasminogen activator activity in blood and the lung tissue and decrease in plasma fibrinogen level as well as decrease in plasma cholesterol. It was a very important finding that in most of the rats the furazabol treatment was effective in reducing susceptibility to lactic acidosis-induced pulmonary thrombosis. No meaningful changes were observed in other parameters tested including ADP-induced platelet aggregability, plasma recalcification time, plasma plasminogen, plasma antiplasmin activity, plasminogen activator content of tissues other than the lungs and the release of vascular activator induced by venous occlusion. One month after cessation of the furazabol treatment, these altered parameters tended to return to normal.

Independently on the furazabol treatment, highly significant positive correlation existed between the plasma activator activity and the pulmonary tissue activator content. This indicated that the major source of plasma activator in the rat was the lung tissue and that the furazabol treatment increased the circulating activator activity through enhancing activator content in the lungs.

 

  • References

  • 1 Abiko Y, Iwamoto M, Shimizu M. 1968; Plasminogen-plasmin system. I. Purification and properties of human plasminogen. Journal of Biochemistry 64: 743.
    PubMedGoogle Scholar
  • 2 Akimoto T, Yamada A, Takayama S, Yotsukura H, Shimada H. 1970; Toxicity of 17β-hydroxy-17α-methyl-5α-androstano [2,3-C] furazan, furazabol (in Japanese). Clinical Report 4: 2031.
    PubMedGoogle Scholar
  • 3 Albrechtson O. K. 1959; Fibrinolytic activity in the organism. Acta Physiologica Scandinavica 47 Supplement 165.
    PubMedGoogle Scholar
  • 4 Astrup T, Buluk K. 1963; Thromboplastic and fibrinolytic activities in vessels of animals. Circulation Research 13: 253.
    CrossrefPubMedGoogle Scholar
  • 5 Astrup T, Müllertz S. 1952; The fibrin plate method for estimating fibrinolytic activity. Archives of Biochemistry and Biophysics 40: 346.
    CrossrefPubMedGoogle Scholar
  • 6 Bielawiec M, Myśliwiec M, Perzanowski A. 1974; The effect of phenformin plus stanozolol on fibrinolysis, platelet adhesiveness and blood lipids in patients with recurrent venous thrombosis. Folia Haematologica 101: 483.
    PubMedGoogle Scholar
  • 7 Born G. V. R. 1962; Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 194: 927.
    PubMedGoogle Scholar
  • 8 Chakrabarti R, Evans J. F, Fearnley G. R. 1970; Effects on platelet stickiness and fibrinolysis of phenformin combined with ethylestrenol or stanozolol. Lancet, I 591.
    PubMedGoogle Scholar
  • 9 Chakrabarti R, Fearnley G. R. 1972; Phenformin and ethylestrenol in survivors of myocardial infarction. Lancet, II 556.
    PubMedGoogle Scholar
  • 10 Ciświcka-Sznajderman M, Bernent H, Rymaszewski Z. 1974; The effect of combined treatment with phenformin and stanozolol on blood lipids and fibrinolytic activity in patients with hypertri-glyceridaemia. Atherosclerosis 19: 153.
    CrossrefPubMedGoogle Scholar
  • 11 Davidson J. F, Lochhead M, McDonald G. A, McNicol G. P. 1972; Fibrinolytic enhancement by stanozolol: a double bind trial. British Journal of Haematology 22: 543.
    CrossrefPubMedGoogle Scholar
  • 12 Davidson J. F, Walker I. D, McCallum H. I. 1974 Study of the mechanism of action of anabolic steroids on fibrinolysis. The Second International Conference on Synthetic Fibrinolytic-Thrombolytic Agents. Paris, September 30. (abstract).
    PubMedGoogle Scholar
  • 13 Fearnley G. R. 1973; Fibrinolysis. Advances in Drug Research 7: 107.
    PubMedGoogle Scholar
  • 14 Fearnley G. R, Chakrabarti R. 1964; Pharmacological enhancement of fibrinolytic activity of blood. Journal of Clinical Pathology 17: 328.
    CrossrefPubMedGoogle Scholar
  • 15 Fearnley G. R, Chakrabarti R, Evans J. F. 1966; Fibrinolytic treatment of rheumatoid arthritis with phenformin plus ethylestrenol. Lancet, II 757.
    PubMedGoogle Scholar
  • 16 Fearnley G. R, Chakrabarti R, Evans J. F. 1969; Fibrinolytic and defibrinating effect of phenformin plus ethylestrenol in vivo. Lancet, I 910.
    PubMedGoogle Scholar
  • 17 Fearnley G. R, Chakrabarti R, Evans J. F. 1971; Mode of action of phenformin plus ethylestrenol on fibrinolysis. Lancet, I 723.
    PubMedGoogle Scholar
  • 18 Fearnley G. R, Chakrabarti R, Hocking E. D. 1967; Fibrinolytic effects of biguanides plus ethylestrenol in occlusive vascular disease. Lancet, II 1008.
    PubMedGoogle Scholar
  • 19 Fossard D. P, Friend J. R, Field E. S, Corrigan T. P, Kakkar V. V, Flute P. T. 1974; Fibrinolytic activity and postoperative deep-vein thrombosis. Lancet, I 9.
    PubMedGoogle Scholar
  • 20 Henly A. A. 1957; Determination of serum cholesterol. Analyst 82: 286.
    PubMedGoogle Scholar
  • 21 Hocking E. D, Chakrabarti R, Evans J. F, Fearnley G. R. 1967; Effect of biguanides and atromid on fibrinolysis. Journal of Atherosclerosis Research 7: 121.
    CrossrefPubMedGoogle Scholar
  • 22 Howe P. E. 1921; The use of sodium sulfate as the globulin precipitant in the determination of proteins in blood. Journal of Biological Chemistry 49: 93.
    PubMedGoogle Scholar
  • 23 Isacson S, Nilsson I. M. 1970; Effect of treatment with combined phenformin and ethylestrenol on the coagulation and fibrinolytic systems. Scandinavian Journal of Haematology 7: 404.
    PubMedGoogle Scholar
  • 24 Ishizu H, Nobuhara M, Kiyotani T, Saito S, Takata H, Funatsu Y, Ando K. 1972; Studies on fluidity of blood on the basis of fibrinolysis. Part 9. On plasminogen activator of vascular wall and its release. Japanese Journal of Legal Medicine 26: 262.
    PubMedGoogle Scholar
  • 25 Karacharov A. T. 1971; Effect of anabolic steroid preparation on blood coagulation. Klinicheskaia Meditsina 49: 131.
    PubMedGoogle Scholar
  • 26 Kasahara A, Onodera T, Mogi M, Oshima Y, Shimizu M. 1965; Investigations on steroids. V. Pharmacological Studies. (1) Anabolic and androgenic activities of 17β-hydroxy-17α-androstano [2,3-C] furazan (Androfurazanol) a new active anabolic steroid. Chemical and Pharmaceutical Bulletin 13: 1460.
    CrossrefPubMedGoogle Scholar
  • 27 Kuo P. T, Quick R. E. 1970; Improvement of hypertriglyceridemia by anabolic agent in primary type I hyperlipoproteinemia. Circulation 42 (Suppl. 03) 66.
    PubMedGoogle Scholar
  • 28 Mihara H, Fujii T, Okamoto S. 1969; Fibrinolytic activity of cerebro-spinal fluid and the development of artificial cerebral haematomas in dogs. Thrombosis et Diathesis Haemorrhagica 21: 294.
    PubMedGoogle Scholar
  • 29 Miura M. 1965; Activators and proactivator of fibrinolytic system in paranasal mucous membrane of man: two forms of activator of plasminogen and proactivator responsible to streptokinase. Kobe Journal of Medical Sciences 11: 13.
    PubMedGoogle Scholar
  • 30 Nikitin Yu. P, Tabarovskaya T. A. 1969; Fibrinolytic activity of rat tissues. Byulleten Eksperimental noi Biologii i Medistriny 67: 597.
    PubMedGoogle Scholar
  • 31 Nilsson I. M, Hender U, Isacson S. 1974 Phenformin and ethylestrenol in recurrent venous thrombosis. The Second International Conference on Synthetic Fibrinolytic-Thrombolytic Agents, Paris, September 30. (abstract).
    PubMedGoogle Scholar
  • 32 Nilsson I. M, Isacson S. 1973; New aspects of the pathogenesis of thrombo-embolism. Progress in Surgery 11: 46.
    PubMedGoogle Scholar
  • 33 Nilsson I. M, Robertson B. 1968; Effect of venous occlusion on coagulation and fibrinolytic components in normal subjects. Thrombosis et Diathesis Haemorrhagica 20: 397.
    PubMedGoogle Scholar
  • 34 Ohta G, Takegoshi T, Ueno K, Shimizu M. 1965; Synthesis of androstano [2,3-C] furazans and related compounds. Chemical and Pharmaceutical Bulletin 13: 1445.
    CrossrefPubMedGoogle Scholar
  • 35 Onodera T, Ishihara M, Kasahara A, Oshima Y. 1969; The prophylactic effect of 17β-hydroxy-17α-methyl-5α-androstano [2,3-C]-furazan (Furazabol) on experimental atherosclerosis in rabbits (in Japanese). Pharmacometrics 3: 191.
    PubMedGoogle Scholar
  • 36 Reitman S, Frankel S. 1957; A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. American Journal of Clinical Pathology 28: 56.
    CrossrefPubMedGoogle Scholar
  • 37 Sawai Y, Ariga T, Ohshiba S. 1971; Studies on tissue factors of fibrinolytic system: assay method of tissue activator and organ distribution of the activator in hamsters and rats (in Japanese). Nihon University Journal of Medicine 30: 1102.
    PubMedGoogle Scholar
  • 38 Stefanini M, Dameshek W. 1955. The Hemorrhagic. Disorders. Grune & Stratton; New York: 149.
    Google Scholar
  • 39 Sugiyama Y, Okamoto S. 1964; Plasminogen activator in the cytoplasmic granules of rat kidney: studies on extraction by isotonic and hypertonic salt solutions. Kobe Journal of Medical Sciences 10: 257.
    PubMedGoogle Scholar
  • 40 Thorsen S, Brakman P, Astrup T. 1972; Influence of platelets on fibrinolysis: A critical review. In: Ambrus J. L. (ed), Hematologic Review 3: 123.
    PubMedGoogle Scholar
  • 41 Tomikawa M, Ogawa H, Abiko Y. 1974; Experimental model of pulmonary thrombosis in rat. Thrombosis et Diathesis Haemorrhagica 31: 86.
    PubMedGoogle Scholar